David is a Managing Director of Prospect Venture Partners. David co-founded Prospect Venture Partners I, II, and III as dedicated life science funds with over $1 billion under management. David has been actively involved in the formation and growth of numerous successful biomedical and health care companies. He has lead investments and served on the Board of Directors of Gloucester Pharmaceuticals, Healtheon (NASDAQ: HLTH), Kythera Biopharmaceuticals, Lux Biosciences, Microcide Pharmaceuticals (NASDAQ: MCDE), Neurocrine Biosciences (NASDAQ: NBIX), NGM Biopharmaceuticals, Rinat Neuroscience (NYSE: PFE acquired), Senomyx (NASDAQ:SNMX), Trubion Pharmaceuticals (NASDAQ: TRBN) as well as several other privately held companies.

Prior to founding Prospect, David was a Partner at Kleiner Perkins Caufield & Byers (KPCB) where he focused on biomedical product and health care information technology investments from 1993-1997. Prior to KPCB, David spent seven years at Sandoz Pharmaceuticals (presently Novartis) in executive management positions in product marketing, strategic operations and business development in the US and Switzerland. In addition to his operating roles at Sandoz, David managed the company's global venture capital investing activities in affiliation with Avalon Medical Partners from 1992-1993. While at KPCB, David co-founded and served as the CEO of Healtheon Corporation (NASDAQ:HLTH), a pioneering health care transaction company that subsequently merged with WebMD in a $6 billion transaction.

David is also a Principal Partner in the San Francisco Giants, and Manager of Schnell Baseball LLC, a limited partner in SFBA, LP. David received an M.D. from Harvard Medical School, an M.A. in Health Services Research from Stanford University School of Medicine, and a B.S. in Biological Sciences from Stanford University.